Fever is one of the cardinal signs of infection and, nearly 120 years after William Osler's statement in his address to the 47 th annual meeting of the American Medical Association [1] , infectious diseases remain a major cause of morbidity and mortality. Despite this, it is unclear whether fever itself is truly the enemy or whether, in fact, the febrile response represents an important means to help the body fi ght infection. Furthermore, it is unclear whether the administration of antipyretic medications or physical cooling measures to patients with fever and infection is benefi cial or harmful [2] , [3] . Here, we review the biology of fever, the signifi cance of the febrile response in animals and humans, and the current evidence-base regarding the utility of treating fever in intensive care patients with infectious diseases.
The biology of fever

Regulation of normal body temperature
Th ermoregulation is a fundamental homeostatic mechanism that maintains body temperature within a tightly regulated range. Th e ability to internally regulate body temperature is known as endothermy and is a characteristic of all mammals and birds. Th e thermoregulatory system consists of an aff erent sensory limb, a central processing center, and an eff erent response limb. In humans, the central processing center controlling the thermoregulatory set-point is the hypothalamus. Both warm-sensitive and cold-sensitive thermoreceptors are involved in the aff erent limb. Stimulation of the coldsensitive receptors activates eff erent responses relayed via the hypothalamus that reduce heat loss and increase heat production. Th ese responses include reducing blood fl ow to the peripheries and increasing heat production by mechanisms including shivering. Conversely, stimulation of warm-sensitive receptors ultimately increases heat loss through peripheral vasodilation and evaporative cooling caused by sweating.
The cellular and molecular basis of the febrile response
Upward adjustment of the normal hypothalamic thermoregulatory set-point leading to fever is typically part of a cytokine-mediated systemic infl ammatory response syndrome that can be triggered by various infectious etiologies including bacterial, viral, and parasitic infections as well as by a range of non-infectious etiologies including severe pancreatitis and major surgery.
In patients with sepsis, the febrile response involves innate immune system activation via Toll-like receptor 4 (TLR-4). Th is activation leads to production of pyrogenic cytokines including interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Th ese pyrogenic cytokines act on an area of the brain known as the organum vasculosum of the laminae terminalis (OVLT) leading to the release of prostaglandin E 2 (PGE 2 ) via activation of the enzyme cyclo-oxygenase-2 (COX-2). PGE 2 binds to receptors in the hypothalamus leading to an increase in heat production and a decrease in heat loss until the temperature in the hypothalamus reaches a new, elevated, set-point. Once the new set-point is attained, the hypothalamus maintains homeostasis around this new set-point by the same mechanisms involved in the regulation of normal body temperature. However, in addition, there are a number of important specifi c negative feedback systems in place that prevent excessive elevation of body temperature. One key system is the glucocorticoid system, which acts via nuclear factor-kappa B (NF-κB) and activator protein-1 (AP-1). Both these mediators have anti-infl ammatory properties and downregulate the production of pyrogenic cytokines, such as IL-1β, IL-6, and TNF-α. Th e febrile response is further modulated by specifi c antipyretic cytokines including IL-1 receptor antagonist (IL-1RA), IL-10, and TNF-α binding protein.
Heat shock proteins and the febrile response
Th e negative feedback systems outlined above are not the only mechanisms that exist to protect cells from being damaged by the febrile response. In addition, the heat shock proteins (HSPs) provide intrinsic resistance to thermal damage. Genes encoding the HSPs probably fi rst evolved more than 2.5 billion years ago. Th ey represent an important system providing protection to cells, not only against extremes of temperature, but also against other potentially lethal stresses including toxic chemicals and radiation injury. During heat-stress, transcription and translation of HSPs is upregulated. HSPs can then trigger refolding of heat-damaged proteins preserving them until heat-stress has passed or, if necessary, can transport denatured proteins to organelles for intracellular degradation. As well as providing protection against cellular damage from the thermal stress induced by fever, the HSPs may themselves be important regulators of the febrile response. For example, HSP 70 inhibits pyrogenic cytokine production via NF-κB. HSPs also inhibit programmed cell death, which might otherwise be induced by an invading pathogen.
The physiological consequences of fever
Th e febrile response leads to a marked increase in metabolic rate. In humans, generating fever through shivering increases the metabolic rate above basal levels by six-fold [4] . In critically ill patients with fever, cooling reduces oxygen consumption by about 10 % per °C decrease in core temperature and signifi cantly reduces cardiac output and minute ventilation [5] . Any potential benefi t of the febrile response needs to be weighed against this substantial metabolic cost. 
The immunological consequences of fever
The eff ects of fever on the viability of microbial pathogens
Temperatures in the human physiological febrile range cause direct inhibition of some viral and bacterial organisms such as infl uenza virus [6] , Streptococcus pneumonia [7] , [8] , and Neisseria meningitides [9] which can all cause life-threatening illnesses. For infl uenza, the degree of heat sensitivity appears to be a determinant of virulence, such that strains with a shut-off temperature of ≤38 °C cause mild symptoms, whereas strains with a shut-off temperature of ≥39 °C cause severe symptoms [6] . Th e susceptibility of a pathogen to heat may have signifi cance in terms of its pathogenicity in a particular host. For example, Campylobacter jejuni is not pathogenic in birds (body temperature 42 °C) but is pathogenic in humans (body temperature 37 °C) and the growth and chemotactic ability of C. jejuni in vitro are greater at 37 °C than at 42 °C [10] .
The signifi cance of fever in animals with infections
Th e febrile response to infection is seen in a range of animal species including not only endotherms, such as mammals and birds, but also ectotherms, including reptiles, amphibians, and fi sh. Th e febrile response can be blocked by inhibition of COX in a diverse range of species including desert iguanas [11] and bluegill sunfi sh [12] , as well as higher animals like humans. As COX catalyzes the generation of prostaglandins from arachidonic acid, this suggests that the pivotal role of PGE 2 in the regulation of the thermostatic set-point may be preserved in these species as well as in higher animals. Such a common biochemical mechanism to regulate fever across such a diverse group of animals raises the possibility that the febrile response may have evolved in a common ancestor. If this is the case, then fever probably emerged as an evolutionary response more than 350 million years ago [13] . As the febrile response comes at a signifi cant metabolic cost [4] , [5] , its persistence across such a broad range of species provides strong circumstantial evidence that the response has some evolutionary advantage. Furthermore, given that the response appears ubiquitous, it logically follows that the components of the immune system would have evolved to function optimally in the physiological febrile range.
In experimental models in mammals, the febrile response appears to off er a survival advantage across a range of viral infections. Newborn mice infected with coxsackie virus, which are allowed to develop a fever have a much lower mortality than mice which are prevented from developing a fever [14] . Similarly, increasing the environmental temperature from 23-26 °C to 38 °C increases the core temperature of Herpes simplex-infected mice by about 2 °C and increases their survival from 0 % to 85 % [15] . A meta-analysis of the eff ect of antipyretic medications on mortality in animal models of infl uenza infection demonstrated that antipyretic treatment was associated with an increased mortality risk [OR 1.34 (95 % CI 1.04-1.73)] [16] .
Studies in mammalian models of bacterial infections have generally yielded similar results. In rabbits infected with Pasteurella multocida, the presence of a mild fever of up to 2.25 °C above normal was correlated with the greatest chance of survival compared to either normothermia or fever of > 2.25 °C above normal [17] . Although mice are predominantly endothermic, they appear to require external sources of heat to generate a fever. If mice are allowed to position themselves in a cage with a temperature gradient, they increase their ambient temperature preference and elevate their core temperature by 1.1 °C after a lipopolysaccharide (LPS) challenge [18] . Housing mice at 35.5 °C rather than 23 °C increases their core body temperature by about 2.5 °C, alters cytokine expression, and improves survival in Klebsiella pneumoniae peritonitis [19] . In this model, the elevated body temperature seen with increased ambient temperature was associated with a 100,000-fold reduction in the intraperitoneal bacterial load [19] . A recently published systematic review and meta-analysis of the eff ects of antipyretic medications on mortality in S. pneumoniae infection identifi ed four animal studies comparing aspirin to placebo and demonstrated that the administration of aspirin was associated with an increased risk of death [OR 1.97 (95 %CI 1.22-3.19)] [20] .
The signifi cance of fever in humans with infection
Fever, hyperthermia, and antipyresis in non-ICU patients with infections Viral infections
Two double blind randomized placebo-controlled trials in 45 volunteers inoculated with either rhinovirus type 21 (study one) or rhinovirus type 25 (study two) demonstrated that administration of aspirin did not alter the proportion of patients who developed clinical illness or signifi cantly alter the frequency or severity of symptoms [21] . Although the administration of aspirin signifi cantly increased the shedding of rhinovirus in these trials, only one of the 45 patients developed fever so this increase in shedding was probably not attributable to the antipyretic eff ect of aspirin [21] . A similar study of 60 volunteers inoculated with rhinovirus and randomized to aspirin, paracetamol, ibuprofen, or placebo showed that the use of either aspirin or paracetamol was associated with suppression of the serum antibody response and a rise in circulating monocytes [22] . Th ere were no signifi cant diff erences in viral shedding among the four groups. However, the subjects treated with aspirin or paracetamol had a signifi cant increase in nasal symptoms and signs compared to the placebo group [22] . In rhinovirusinfected volunteers treated with pseudo ephe drine, the addition of ibuprofen had no eff ect on symptoms or on viral shedding or viral titers [23] . Again, only two of the 58 subjects developed a fever. A randomized controlled trial of children aged six months to six years with presumed non-bacterial infection and a fever of ≥ 38 °C demonstrated that administration of paracetamol increased the children's activity but not their mood, comfort or appetite [24] .
Overall, the data from clinical studies in non-ICU patients do not support the hypothesis that antipyresis has a clinically signifi cant benefi cial or detrimental impact on the course or severity of minor viral illnesses. Although antipyretic medicines may increase the duration of rhinovirus shedding and time until crusting of chicken pox lesions, these eff ects seems unlikely to be attributable to antipyresis and are of uncertain clinical importance.
Bacterial infections
Th ere are no randomized controlled trial data examining strategies of fever management on patient-centered outcomes in non-ICU patients with bacterial infections. However, there are historical examples of dramatic responses to treatment with therapeutic hyperthermia in some infectious diseases. It has been known since the time of Hippocrates that progressive paralysis due to neurosyphilis sometimes resolves after an illness associated with high fever. Th is observation led Julius Wagner-Jauregg to propose, in 1887, that inoculation of malaria might be a justifi able therapy for patients with 'progressive paralysis' . His rationale was that one could substitute an untreatable condition for a treatable onemalaria being treatable with quinine. In 1917, he tested his hypothesis in nine patients with paralysis due to syphilis by injecting them with blood from patients suff ering from malaria. Th ree of the patients had remission of their paralysis. Th is led to further experiments and clinical observations on more than a thousand patients with remission occurring in 30 % of patients with neurosyphilis-related progressive paralysis 'treated' with fever induced by malaria compared to spontaneous remission rates of only 1 %. Th is work on fever therapy led to Julius Wagner-Jauregg being awarded the Nobel Prize in Physiology or Medicine in 1927 [25] . Subsequently, fever therapy was shown to be eff ective in treating gonorrhea. Inducing a hyperthermia of 41.7 °C for six hours in the 'Kettering hypertherm chamber' led to cure in 81 % of cases [26] .
A number of observational studies have examined the association between body temperature and outcome in patients with various bacterial infections, including pneumonia [27] , spontaneous bacterial peritonitis [28] , and Gram-negative bacteremia [29] . Th ese studies show that the absence of fever is a sign of poor prognosis in patients with bacterial infections. Overall, the design of these studies does not allow one to distinguish between the absence of fever as a marked of disease severity or impaired host resilience rather than the presence of fever as a protective response.
Fever in ICU patients with infections Observational studies of fever and fever management in ICU patients
Th e epidemiology of fever in ICU patients and the frequency and utility of antipyretic use in ICU patients has been evaluated in a number of observational studies. Th e most important of the studies are summarized in Table 1 .
Th e incidence of fever attributable to infection in observational studies in various critical care settings varies from 8 % to 37 % [31] , [34] , [36] - [41] . Th ese studies use a variety of defi nitions of fever and a range of methods to record temperature, making comparisons between studies diffi cult. In these studies, the presence of fever was associated with either an increased risk of death [30] , [39] - [41] or no diff erence in mortality risk compared to a normal temperature [34] . Only two studies have evaluated the mortality risk of patients with sepsis separately from patients without sepsis [33] , [35] . In the fi rst study, fever was associated with an increased 28-day mortality risk in patients without sepsis but not in patients with sepsis [33] raising the possibility that the presence of infection might be an important determinant of the signifi cance of the febrile response in ICU patients. Similarly, in a retrospective cohort study [35] (n = 636,051) using two independent, multicenter, geographically distinct and representative databases we found that peak temperatures above 39.0 °C in the fi rst 24 hours after ICU admission were generally associated with a reduced risk of in-hospital mortality in patients with an admission diagnosis of infection. Conversely, higher peak temperatures were associated with an increased risk of in-hospital mortality in patients with a non-infection diagnosis. Overall, although one recent study suggests that the incidence of fever is decreasing over time [36] , existing observational data suggest that fever is a commonly encountered abnormal physical sign in ICU patients. Unfortunately, because of the potential for unmeasured confounding factors, it is impossible to establish whether treating fever in ICU patients with an infection is benefi cial or harmful on the basis of observational studies.
Interventional studies of fever management in ICU patients
Two recently published meta-analyses found no evidence that antipyretic therapy was either benefi cial or harmful in non-neurologically injured ICU patients [2] , [3] . Nearly all of the patients included in these meta-analyses had known or suspected sepsis and one of the metaanalyses only included patients with infection [3] . In both meta-analyses, the authors noted that existing studies lacked adequate statistical power to detect clinically important diff erences and recommended that large randomized controlled trials were urgently needed. Th e details of published interventional studies of fever management strategies in ICU patients are summarized in Table 2 .
Th e largest published randomized controlled trial evaluated the use of ibuprofen in critically ill patients with sepsis [43] . Patients with severe sepsis were randomized to receive 10 mg/kg of ibuprofen or placebo every six hours for a total of eight doses. Although the use of ibuprofen signifi cantly reduced body temperature, it did not alter 30-day mortality, which was 37 % in the ibuprofen-treated group and 40 % in the placebo group. Th is study was designed to evaluate the use of ibuprofen as an anti-infl ammatory rather than as an anti-pyretic and, while the use of ibuprofen signifi cantly reduced temperature compared to placebo, the study included patients who were hypothermic as well as patients who were febrile. An additional confounding factor was that patients assigned to the ibuprofen group were treated with paracetamol more often than those assigned to the control group. On the basis of this [43] and other smaller studies [45] , [46] of non-steroidal anti-infl ammatory drugs (NSAIDs) in critically ill patients, it is clear that NSAIDs are eff ective at reducing temperature in febrile ICU patients. However, there is no consistent mortality signal from the existing studies of NSAIDs. Some studies show trends towards benefi t [42] - [44] with the use of NSAIDs and others show trends towards harm [45] , [46] .
Th e second largest published study of temperature management in febrile ICU patients evaluated the use of external cooling [49] . Th is study randomized 200 febrile patients with septic shock requiring vasopressors, mechanical ventilation, and sedation to external cooling to normothermia (36.5-37 °C) for 48 hours or no external cooling. Th e primary endpoint was the proportion of patients with a 50 % decrease in vasopressor use at 48 hours after randomization. Th ere was no signifi cant diff erence between the treatment groups for the primary endpoint, which was achieved in 72 % of the patients assigned to external cooling and 61 % of the patients assigned to standard care. Th is study had a large number of secondary endpoints including mean body temperature, the proportion of patients who achieved 50 % reduction in vasopressors at 2 hours, 12 hours, 24 hours, and 36 hours as well as day-14, ICU, and hospital mortality. Th e secondary endpoints generally favored external cooling and day-14 mortality was noted to be signifi cantly lower in the external cooling group (19 % vs. 34 %; p = 0.0013). Th is diff erence in mortality was not evident by the time of ICU or hospital discharge and caution should be exerted in interpreting these endpoints as it is possible that they were aff ected by a type 1 error due to a lack of statistical power.
Another trial compared temperature control strategies in a tertiary trauma ICU and randomized patients to either aggressive temperature control or a permissive strategy [47] . Patients assigned to the aggressive treatment arm received regular paracetamol once the temperature exceeded 38.5 °C and physical cooling was added when the temperature exceeded 39.5 °C. Patients assigned to the permissive treatment arm received paracetamol and cooling when the temperature reached 40 °C. Th is trial originally aimed to enroll 672 patients; however, it was stopped by the Data Safety Monitoring Board after enrolment of 82 patients due to a trend towards increased mortality in the aggressive treatment group. While all deaths were attributed to septic causes, conventional stopping rules were not used and diff erences between the study treatment arms could be due to chance. Th is study had other major limitations including a lack of blinding or placebo-control, and potential confounding from the uncontrolled use of other antipyretic drugs and per-protocol use of external cooling. A similar open-label randomized study enrolled 26 febrile ICU patients and assigned them to aggressive or permissive temperature management [48] . In this study, the aggressive fever control group received paracetamol 650 mg enterally every 6 hours when the temperature was ≥ 38.3 °C and received physical cooling for temperature ≥ 39.5 °C. Th e permissive group did not receive paracetamol until the temperature was ≥ 40 °C and did not receive physical cooling until the temperature reached ≥ 40.5 °C. All patients assigned to aggressive temperature management had an infectious etiology of fever and 75 % of patients assigned to the permissive management arm had an infectious etiology at baseline. Th e 28-day all cause mortality was not signifi cantly diff erent between the two groups.
Th e safety and effi cacy of using paracetamol to treat fever in ICU patients with infections is being evaluated in a 700-patient phase IIb, multicenter, randomized placebo-controlled trial (the HEAT trial), which is due to complete enrolment in November 2014 [50] . • All doses of ibuprofen tested were eff ective in lowering temperature • There were no signifi cant diff erence between treatment groups with respect to ventilation requirements, length of stay or in-hospital mortality (4 % placebo, 3 % 100 mg ibuprofen, 7 % 200 mg ibuprofen, 6 % 400 mg ibuprofen)
Haupt et al. 1991 [46] Multicenter, placebo-controlled randomized trial of ibuprofen in patients with severe sepsis; n = 29
• Ibuprofen signifi cantly reduced body temperature • There was no signifi cant diff erence between the treatment groups in terms of in-hospital mortality (30.8 % in the placebo group vs. 56.3 % in the ibuprofen group)
Schulman et al. 2006 [47] Single center, unblinded, randomized trial of aggressive vs. permissive temperature management in febrile patients in a trauma ICU; n = 82
• There was no signifi cant diff erence between the treatment arms in terms of the number of new infections • The in-hospital mortality was 15.9 % in the aggressive treatment group and 2.6 % in the permissive treatment group (p = 0.06)
Niven et al. 2012 [48] Multicenter, unblinded randomized trial of aggressive vs. permissive temperature management in febrile ICU patients; n = 26
• The mean daily temperature was lower in the patients assigned to aggressive fever management • The in-hospital mortality was 21 % in the aggressive treatment group and 17 % in the permissive treatment group (p = 1.0)
Schortgen et al. 2012 [49] Multicenter, randomized controlled trial of external cooling in patients with fever and septic shock receiving mechanical ventilation in seven centers in France; n = 200
• External cooling signifi cantly reduced body temperature • External cooling did not alter the proportion of patients who had a 50 % reduction in vasopressor dose after 48 hours • Day-14 mortality was signifi cantly lower in the patients assigned to external cooling but there was no signifi cant diff erence between the groups in terms of ICU or in-hospital mortality ARDS: acute respiratory distress syndrome; ICU: intensive care unit.
Young and Saxena Critical Care 2014, 18:206 http://ccforum.com/content/18/2/206
Conclusion
Th ere is a signifi cant body of animal data demonstrating that fever is an important component of the host response to infection and confers a survival advantage in a number of animal species. Th e conservation of a metabolically costly response across a broad range of animal species suggests that the response probably has an evolutionary advantage. Th ere are some interesting historical examples of hyperthermia being employed to treat infectious diseases. However, in the modern era the relevance of these examples is questionable. Furthermore, arguments based on the evolutionary importance of the febrile response do not necessarily apply to critically ill patients who are, by defi nition, supported beyond the limits of normal physiological homeostasis. Humans are not adapted to critical illness. In the absence of modern medicine and intensive care, most critically ill patients with fever and infection would presumably die. Among critically ill patients, it is biologically plausible that there is a balance to be struck between the potential benefi ts of reducing metabolic rate that come with fever control and the potential risks of a deleterious eff ect on host defense mechanisms. Remarkably, at present, we do not know what eff ect treating fever in critically ill patients with infections has on patient-centered outcomes. Th ese treatments include commonly used interventions such as paracetamol and physical cooling. Th is area of research is of high priority given the global epidemiology of fever in critically ill patients and the generalizability of the candidate interventions.
